---
document_datetime: 2024-08-29 11:20:50
document_pages: 42
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/karvezide-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: karvezide-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 28.8720276
conversion_datetime: 2025-12-31 07:41:37.288241
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Karvezide

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0218               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                      | 28/08/2024                          |                                             | PL                               |           |
| IA/0217              | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate | 18/06/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                             |            |            |                     |                                                                                                                                                 |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2502 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.3 of the SmPC in order to update information on hydrochlorothiazide monocomponent based on literature review. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/01/2024 | 22/05/2024 | SmPC                | Section 5.3 of the SmPC has been updated to state that evidence of a genotoxic or carcinogenic effect was observed in some experimental models. |
| IG/1675 | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                         | 27/10/2023 | 22/05/2024 | Annex II            |                                                                                                                                                 |
| N/0215  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                  | 29/06/2023 | 22/05/2024 | PL                  |                                                                                                                                                 |
| WS/2452 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                       | 12/05/2023 | 22/05/2024 | Annex II            |                                                                                                                                                 |
| T/0212  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                               | 23/11/2022 | 12/12/2022 | SmPC, Labelling and |                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            | PL              |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IG/1509             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                   | 17/06/2022 | n/a        |                 |                                   |
| WS/2267/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a | 16/06/2022 | n/a        |                 |                                   |
| PSUSA/10601 /202108 | Periodic Safety Update EU Single assessment - irbesartan, irbesartan / hydrochlorothiazide                                                                                                                                                                                                                                                                                                                                                                                                                                    | 07/04/2022 | n/a        |                 | PRAC Recommendation - maintenance |
| IG/1451             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 15/02/2022 | 13/09/2022 | Annex II and PL |                                   |
| IB/0208             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/02/2022 | 13/09/2022 | SmPC and PL     |                                   |

<div style=\"page-break-after: always\"></div>

| WS/2180   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   | 02/12/2021   | n/a        |          |                                                                           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|---------------------------------------------------------------------------|
| WS/2172   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   | 25/11/2021   | n/a        |          |                                                                           |
| WS/2122   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                 | 23/09/2021   | 13/09/2022 | Annex II | Update of Annex II of the product information and lifting of condition D. |
| IG/1378   | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                                                                                                     | 20/04/2021   | n/a        |          |                                                                           |

<div style=\"page-break-after: always\"></div>

| WS/1969   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC in order to add anemia to the list of adverse drug reactions with frequency unknown based on a review of the available data including the MAH database and a literature review; the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                        | 25/03/2021   | 10/05/2021   | SmPC and PL   |                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------------|
| A31/0188  | The European Commission triggered a referral under Article 31 of Directive 2001/83/EC and requested the CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinal products and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked. During the CHMP plenary meeting in September 2018, the scope of the referral has been widened to include all sartans with a tetrazole group in their molecular structure (candesartan, irbesartan, losartan, olmesartan and valsartan). The CHMP Opinion was issued on 31 January 2019 and the Commission Decision was issued on 2 April 2019. In a letter dated 29 July 2020, the European Commission requested the EMA to assess the impact of the outcome of the Article 5(3) assessment on | 12/11/2020   | 12/02/2021   | Annex II      | Please refer to the assessment report: Karvezide EMEA/H/A-31/1471/C/221/0188 |

<div style=\"page-break-after: always\"></div>

|           | nitrosamines adopted on 25 June 2020 on the CHMP's opinion of 31 January 2019 for the scientific assessment and review under Article 31 of Directive 2001/83/EC regarding angiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471). The CHMP was requested to give its recommendation whether the conditions of the Marketing Authorisations should be varied.                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1886/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Group of variations consisting of: C.I.4 - Update of section 4.4 and 4.8 of the SmPC to add information on hypoglycaemia based on a review of available data including the MAH pharmacovigilance data base and a literature review. The Package leaflet is updated accordingly. C.I.4 - Update of 4.4 and 4.5 of the SmPC to add information on a drug -drug interaction with irbesartan and repaglinide based on a review of the available data including the MAH database and a literature review. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to implement the updated annex to the European Commission guideline on Excipients in the labelling | 14/01/2021 | 10/05/2021 | SmPC and PL | Based on a review of the available data including the MAH database and a literature review information was added to the SmPC to inform that irbesartan may induce hypoglycaemia, particularly in diabetic patients. In patients treated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required when indicated. Hypoglycaemia has been added as an undesirable effect under frequency not known. Irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that irbesartan increased the Cmax and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3 fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant pharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose adjustment of antidiabetic treatment such as repaglinide may be required. The product leaflet is updated accordingly. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|           | and package leaflet of medicinal products for human use' to update the excipient sodium. The MAH also took the opportunity to update the list of local representatives in the PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data               |            |            |             | Product Characteristics.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------|
| IB/0201   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                      | 21/08/2020 | 10/05/2021 | SmPC and PL |                            |
| IG/1272   | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                 | 23/07/2020 | n/a        |             |                            |
| IB/0196/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new | 07/05/2020 | 10/05/2021 | Annex II    |                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| corresponding test method B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.III.2.b - Change to national pharmacopoeia to comply with an update of the Ph. Eur. or national   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IG/1220/G   | a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate manufacturer   | 27/03/2020   | n/a        |    | This was an application for from an already approved   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|--------------------------------------------------------|
| N/0195      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                       | 26/02/2020   | 10/05/2021 | PL |                                                        |
| IG/1186     | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                            | 20/12/2019   | n/a        |    |                                                        |
| IG/1187     | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                            | 19/12/2019   | n/a        |    |                                                        |
| IB/0192/G   | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold                                                                                                                                                                    | 14/10/2019   | n/a        |    |                                                        |

<div style=\"page-break-after: always\"></div>

|           | compared to the originally approved batch                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        | increase size   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------|
| IG/1076   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 05/04/2019 | n/a        |                        |                 |
| IG/1022   | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/12/2018 | n/a        |                        |                 |
| IAIN/0190 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/12/2018 | 02/04/2019 | SmPC and PL            |                 |
| WS/1346   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 4.8 of the SmPC to add 'anaphylactic reaction including anaphylactic shock' to the list of adverse drug reactions. The PL is updated accordingly. In addition, the MAH took the opportunity to update the information on local representatives in Bulgaria and Germany and to update the product information in line with the latest QRD template (version 10). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/07/2018 | 20/09/2018 | SmPC, Labelling and PL |                 |

<div style=\"page-break-after: always\"></div>

| IG/0890            | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/02/2018   | n/a        |                 |                                                                                                                                           |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0185/G          | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 19/09/2017   | 20/09/2018 | Annex II and PL |                                                                                                                                           |
| PSUSA/1653/ 201609 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / irbesartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/06/2017   | 24/08/2017 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1653/201609. |
| IG/0830            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/08/2017   | n/a        |                 |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IB/0183   | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/07/2017   | n/a   | ASMF          |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------|
| IB/0182/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold compared to the originally approved batch | 02/06/2017   | n/a   | increase size |
| IB/0179/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other                                                                                                                              | 05/01/2017   | n/a   | variation     |

<div style=\"page-break-after: always\"></div>

| IA/0178/G   | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   | 07/11/2016   | n/a        |             |                                                                                                                                    |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------|
| N/0177      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                             | 24/09/2015   | 24/08/2017 | PL          |                                                                                                                                    |
| N/0176      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                             | 17/03/2015   | 24/08/2017 | PL          |                                                                                                                                    |
| IB/0175     | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                 | 19/02/2015   | n/a        |             |                                                                                                                                    |
| A31/0165    | On 17 April 2013, further to the emergence of new evidence from the scientific literature on dual RAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the Pharmacovigilance Risk Assessment Committee (PRAC) to issue a recommendation on the benefit-                                     | 22/05/2014   | 04/09/2014 | SmPC and PL | For further information please refer to the Renin- angiotensin-system (RAS)-acting agents Article 31 referral - Assessment report. |

<div style=\"page-break-after: always\"></div>

|                    | risk of dual RAS blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure.   |            |     |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IG/0454            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                              | 17/07/2014 | n/a |                                   |
| PSUSA/1653/ 201309 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / irbesartan                                                                                                                                                                                                                                               | 13/06/2014 | n/a | PRAC Recommendation - maintenance |
| IA/0173            | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                          | 14/05/2014 | n/a |                                   |
| IA/0172            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                 | 30/04/2014 | n/a |                                   |
| IA/0171/G          | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the                                                                                                                                                                       | 31/03/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                             |            |            |                                  |                                                                              |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------|
| IA/0169 | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                     | 31/03/2014 | n/a        |                                  |                                                                              |
| IA/0170 | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                      | 21/03/2014 | n/a        |                                  |                                                                              |
| N/0168  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                | 19/02/2014 | 04/09/2014 | PL                               |                                                                              |
| IG/0327 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                  | 02/08/2013 | n/a        |                                  |                                                                              |
| II/0158 | Update of SmPC sections 4.3, 4.4 and 4.5 to reflect that the concomitant use of Angiotensin II Receptor Blockers (ARBs) with aliskiren is contraindicated in patients with renal impairment and in patients with diabetes mellitus. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to align the annexes with the latest QRD template, to make editorial changes in the annexes and to introduce the contact details of the local representative in Croatia in the Package Leaflet. | 27/06/2013 | 31/07/2013 | SmPC, Annex II, Labelling and PL | Please refer to the Scientific Discussion \"Karvezide-EMEA- H-C-0221-II-158\". |

<div style=\"page-break-after: always\"></div>

|         | C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH   |            |            |                 |           |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------|
| IA/0164 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                 | 05/06/2013 | 31/07/2013 | Annex II and PL |           |
| IB/0161 | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                                                                   | 06/05/2013 | n/a        |                 |           |
|         | B.III.1.a.3 - Submission of a new or updated Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                       | 02/05/2013 | n/a        |                 | IAIN/0163 |
| IA/0162 | B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter                                                                     | 26/04/2013 | n/a        |                 |           |
| II/0159 | Change in the specifications limits range for the active substance Irbesartan. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the specifications limits range for the AS  | 25/04/2013 | n/a        |                 | approved  |

<div style=\"page-break-after: always\"></div>

| IA/0160   | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size                                                                                                                                                                                                                                                                                                  | 22/04/2013   | n/a        |                        |                                                                           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------------------------|
| T/0157    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                          | 01/02/2013   | 18/02/2013 | SmPC, Labelling and PL | Transfer of the Marketing Authorisation to sanofi-aventis groupe, France. |
| IA/0155   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size                                                                                                                                                                                                                                                                                                    | 20/12/2012   | n/a        |                        |                                                                           |
| IG/0254   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                               | 17/12/2012   | n/a        |                        |                                                                           |
| IA/0154   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                | 03/12/2012   | n/a        |                        |                                                                           |
| IB/0153/G | This was an application for a group of variations. B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 15/10/2012   | n/a        |                        |                                                                           |

<div style=\"page-break-after: always\"></div>

| II/0151   | This type II variation application concerns an update of section 4.4 of the SmPC to include a warning on the risk of 'acute myopia' and 'secondary acute angle-closure glaucoma' associated with the use of hydrochlorothiazide. Further, section 4.8 of the SmPC has been updated to include the two ADRs 'acute myopia' and 'secondary acute angle-closure glaucoma' and the Package Leaflet has been updated accordingly. In addition, the MAH has taken the opportunity to implement editorial changes to the annexes and to revise the annexes in line with the latest QRD template (version 8.1). C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   | 24/05/2012   | 27/06/2012   | SmPC, Annex II, Labelling and PL   | A total of six cases of 'Acute Myopia' and 'Secondary Acute Angle-Closure Glaucoma' were identified following a comprehensive literature review by the MAH. Two of them were considered related to the combination of irbesartan and HCTZ. Five cases reported bilateral 'acute angle- closure glaucoma' and one reported 'acute myopia' and 'perimacular oedema'. It is acknowledged that concomitant drugs and medical history are potential confounding factors in all cases identified, but nevertheless a role of HTCZ in these cases cannot be ruled out. Although the number of reported cases of 'acute angle- closure glaucoma' and 'acute myopia' is very small, the CHMP was of the view that this information should be reflected as a warning in the SmPC due to the seriousness of these ADRs that can lead to important visual disability, and the fact that other sulfa-derivated drugs have also been reported to cause the ADRs bilateral 'acute myopia' and 'acute angle-closure glaucoma'. Therefore, it was agreed to add the following warning to the SmPC: ''Acute Myopia and Secondary Acute Angle-Closure Glaucoma: sulfonamide drugs or sulfonamide derivative drugs can cause an idiosyncratic reaction, resulting in transient myopia and acute angle-closure glaucoma. While hydrochlorothiazide is a sulfonamide, only isolated cases of acute angle-closure glaucoma have been reported so far with hydrochlorothiazide. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                       |            |            |             | rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.' The overall benefit-risk balance for the combination irbesartan + HCTZ remains unchanged.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0152   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                | 21/06/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                          |
| IB/0150/G | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                      | 13/03/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                          |
| IA/0149   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                   | 20/02/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                          |
| IB/0147   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Change(s) | 16/02/2012 | 27/06/2012 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | with new additional data submitted by the MAH C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                           |            |            |      |                                                                                                                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------|
| IA/0148/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size | 19/01/2012 | n/a        |      |                                                                                                                   |
| IB/0145   | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                                                                                                                                                                                                        | 13/01/2012 | n/a        |      |                                                                                                                   |
| IB/0144   | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size                                                                                                                                                                                                                                        | 10/01/2012 | n/a        |      |                                                                                                                   |
| IB/0146   | B.I.a.3.z - Change in batch size (including batch size ranges) of AS or intermediate - Other variation                                                                                                                                                                                                                                                                                             | 04/01/2012 | n/a        |      |                                                                                                                   |
| WS/0171   | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                               | 22/09/2011 | 20/10/2011 | SmPC | This type IB variation concerns an update of SmPC sections 4.6 and 5.3, upon request by CHMP, with agreed wording |

<div style=\"page-break-after: always\"></div>

|         | Commission Regulation (EC) No 1234/2008. Update of Summary of Product Characteristics C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                  |            |            |             | regarding fertility. It is unknown whether irbesartan or its metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its metabolites in milk. Fertility and reproductive performance were not affected in studies of male and female rats even at oral doses of irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the highest dose. No significant effects on the number of corpora lutea, implants, or live fetuses were observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals indicate that the radiolabeled irbesartan is detected in rat and rabbit fetuses. This application was submitted following a worksharing procedure according to Article 20 of Commission Regulation   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0147 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.3.b - Implementation of change(s) requested | 21/07/2011 | 18/08/2011 | SmPC and PL | This type II variation concerns an update of section 4.5 of the SmPC, upon request by the CHMP following the assessment of PSUR 9, to include information about the potential interaction between hydrochlorothiazide and carbamazepine. Concomitant use of carbamazepine and hydrochlorothiazide has been associated with the risk of symptomatic hyponatraemia. Therefore, electrolytes should be monitored during concomitant use, and if possible, another class of diuretics should be used. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to put the annexes in line with the latest QRD template (version 7.3.1). This application was submitted as a Type II variation following a worksharing procedure according to Article 20                                                                           |

<div style=\"page-break-after: always\"></div>

|           | following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                            |            |            |             | of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0141   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                          | 27/05/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| WS/0074   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of Summary of Product Characteristics and Package Leaflet C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the | 14/04/2011 | 18/05/2011 | SmPC and PL | This type IB variation concerns an update of section 4.8 of the SmPC with the ADR 'jaundice', upon request by the CHMP following the assessment of irbesartan PSUR 15 and FU2 020.1. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make some editorial changes in the SmPC and Package Leaflet. This application was submitted following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. |
| IA/0140   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                    | 04/05/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0137/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used                                                                                                                                                                                                                                                            | 08/04/2011 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | in the manufacture of the AS A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                           |            |     |          |                               |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|-------------------------------|
| IB/0139   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                          | 06/04/2011 | n/a |          |                               |
| IA/0138   | C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the                                                                                      | 29/03/2011 | n/a | Annex II | DD                            |
| IA/0136/G | application for a group of variations. C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the of the QPPV | 28/10/2010 | n/a | Annex II | This was an back-up procedure |
| IA/0135   | B.III.2.a.1 - Change of specification('s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                                                                                                                                                                       | 06/07/2010 | n/a |          |                               |

<div style=\"page-break-after: always\"></div>

| IB/0134   | B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF                                                                                                                                                                                                                                                              | 10/06/2010   | n/a        |          |                                                                                                                                                                        |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0133   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                             | 19/05/2010   | n/a        |          |                                                                                                                                                                        |
| N/0132    | To change the phone number of the Slovak local representative in the Package Leaflet. Furthermore the Marketing Authorisation Holder took this opportunity to make linguistic amendments to the Dutch and French Package Leaflets. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                      | 27/04/2010   | n/a        | PL       |                                                                                                                                                                        |
| IA/0131/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system | 22/03/2010   | n/a        | Annex II |                                                                                                                                                                        |
| II/0127   | Update of SPC section 4.8 upon request by CHMP following the assessment of the renewal of Karvezide (EMEA/H/C/000221/R/0114), with respect to the                                                                                                                                                                                                                        | 17/12/2009   | 03/02/2010 | SmPC     | This Type II variation was submitted in order to update section 4.8 (Undesirable effects) of the SmPC based on a request from the CHMP following the assessment of the |

<div style=\"page-break-after: always\"></div>

|         | introductory paragraph and the estimate of the overall percentage of treated patients to experience adverse reactions. Update of Summary of Product Characteristics                                              |            |            |             | renewal of Karvezide to provide information on adverse reactions according to the EU SmPC Guideline (October 2005), as well as to include a general description on what are the most serious and/or most frequently occurring adverse drug reactions. In support to this application, the MAH submitted a review of the Integrated Summary of Safety (ISS) as well as cumulative data from placebo- controlled hypertensive trials CV131-037,-038,-039, and - 040. The updated section 4.8 includes now the following paragraph: Irbesartan/hydrochlorothiazide combination: Among 898 hypertensive patients who received various doses of irbesartan/hydrochlorothiazide (range: 37.5 mg/6.25 mg to 300 mg/25mg) in placebo-controlled trials, 29.5% of the patients experienced adverse reactions. The most commonly reported ADRs were dizziness (5.6%), fatigue (4.9%), nausea/vomiting (1.8%), and abnormal urination (1.4%). In addition, increases in blood urea nitrogen (BUN) (2.3%), creatine kinase (1.7%) and creatinine (1.1%) were also commonly observed in the trials. Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled trials.   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0130 | IB_38_c_Change in test procedure of finished product - other changes                                                                                                                                             | 07/01/2010 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0128 | Update of Summary of Product Characteristics (SPC) section 4.5 and Package Leaflet section 2 regarding information on the interaction of hydrochlorothiazide (HCTZ) with cholestyramin and colestipol resins. In | 19/11/2009 | 21/12/2009 | SmPC and PL | With this application, in SPC section 4.5 the existing statement regarding an interaction with colestyramine and colestipol resins has been amended indicating that irbesartan + hydrochlorothiazide should be taken at least                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | particular to provide further guidance in the SPC to physicians on the recommended time between the administration of irbesartan + HCTZ and cholestyramin and colestipol resins. Update of Summary of Product Characteristics and Package Leaflet   |            |            |    | one hour before or four hours after these medications. A literature search was performed by the MAH to identify studies leading to a drug interaction between irbesartan, hydrochlorothiazide and cholestyramine. In a study with ten healthy adult male subjects evaluating appropriate dosing schedules of cholestyramine to minimize its effect on absorption, the investigators reported that the best dosing schedule for cholestyramine is 4 hours after hydrochlorothiazide (Hunninghake and Hibbard, 1986). On the other hand, it has been recommended that the administration of cholestyramine or colestipol have to be separated from the time of other medications (e.g. HCTZ) by 1-2 hours to minimize their effects on the absortion (Lamrini et al 1997; Hunninghake et al 1982).   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0129 | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)                                                                                                                                                            | 02/12/2009 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| N/0126  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                    | 09/10/2009 | n/a        | PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0125 | Change of the manufacturing site of irbesartan and as a consequence a change in the batch size of this active substance. Change(s) to the manufacturing process for the active substance                                                            | 24/09/2009 | 05/10/2009 |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0124 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                    | 08/07/2009 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0123 | IA_11_a_Change in batch size of active substance or                                                                                                                                                                                                 | 26/06/2009 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | intermediate - up to 10-fold                                                                                                                                                                                                                                                                                                                                                                       |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0120 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                                                              | 23/06/2009 | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0122 | IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing                                                                                                                                                                                                                                                                                                       | 10/06/2009 | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0121 | IA_32_a_Change in batch size of the finished product - up to 10-fold                                                                                                                                                                                                                                                                                                                               | 20/05/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0119 | IB_10_Minor change in the manufacturing process of the active substance                                                                                                                                                                                                                                                                                                                            | 17/04/2009 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0118 | The MAH applied for an update of the SPC sections 4.3 and 4.6 as well as PL section 2 to implement the CHMP recommendation on a harmonised labelling relating to the use of Angiotensin II Receptor Antagonists during pregnancy and lactation. Furthermore, minor typographical changes have been introduced to SPC section 4.4. Update of Summary of Product Characteristics and Package Leaflet | 19/02/2009 | 27/03/2009 | SmPC and PL | Available data regarding use of AIIRAs during lactation have been assessed. There are no concrete data to support the contraindication of use of AIIRAs during breast-feeding. All AIIRA agents were found in the milk of lactating rats but no human data about their transfer into breast milk are available. There is only a theoretical presumption of low transport according to their high plasma protein binding and low oral availability. A harmonised wording recommending an alternative treatment with better established safety profiles during breast-feeding, especially while nursing a newborn or preterm infant, has been included in the section 4.6 of the SPC and section 2 of the PL. Consequently, the existing contraindication for lactation has |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                 |            |            |                        | been deleted.                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0117 | Update of Detailed Description of the Pharmacovigilance System Changes to QPPV Update of DDPS (Pharmacovigilance)                                               | 22/01/2009 | 26/02/2009 | Annex II               | The Detailed Description of the Pharmacovigilance System has been updated (Version 3.0) to reflect the change of the Qualified Person for Pharmacovigilance (QPPV) as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS.                                                                                      |
| R/0114  | Renewal of the marketing authorisation.                                                                                                                         | 24/07/2008 | 01/10/2008 | SmPC, Labelling and PL | Based on the CHMP review of the available information and on the basis of the re-evaluation of the benefit-risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit/risk profile of Karvezide continues to be favourable. The CHMP was also of the opinion that the renewal can be granted with unlimited validity. |
| IB/0116 | IB_10_Minor change in the manufacturing process of the active substance IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold        | 18/08/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0115 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                | 29/07/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0109 | Update of Summary of Product Characteristics and Package Leaflet The MAH applied for an update of the SPC sections 4.3, 4.4, and 4.6 as well as PL section 2 to | 24/04/2008 | 10/06/2008 | SmPC and PL            | Cooper's study published in the NEJM in June 2006 identified a signal of increased risk of congenital malformations, particularly cardiac defects after exposure to ACE inhibitors during the first trimester of pregnancy. Since the role of confounding factors such as diabetes and                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | implement the CHMP recommendation on a harmonised labelling relating to the use of ACE inhibitors and Angiotensin II Receptor Antagonists during pregnancy. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                       |            |     |                 | hypertension cannot be accurately defined based on the available data, the teratogenic potential of ACE inhibitors is not demonstrated, even though data suggest that such exposure cannot be considered as safe and should be avoided. There are fewer data regarding the risks associated with first trimester exposure to Angiotensin II receptor antagonists (AIIRAs) than for ACE inhibitors. Nevertheless, there is no evidence that the risk is lower for AIIRAs, and it is considered that any conclusions on ACE inhibitors are also valid for AIIRAs. Therefore, the existing contraindication for the 2nd and 3rd trimester of pregnancy remained, but a harmonised wording regarding pregnancy across the class was introduced.   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0111 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing | 08/05/2008 | n/a | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0113 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                         | 07/05/2008 | n/a | SmPC            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0112 | IB_10_Minor change in the manufacturing process of the active substance IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                           | 25/04/2008 | n/a |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IA/0110   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                               | 03/04/2008   | n/a   |                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------|
| IA/0108   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                               | 13/02/2008   | n/a   |                 |
| IA/0107   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                                                                                                                                               | 13/12/2007   | n/a   |                 |
| N/0106    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                   | 07/12/2007   | n/a   | PL              |
| IA/0105   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                                                                                                                   | 27/09/2007   | n/a   |                 |
| IB/0104   | IB_10_Minor change in the manufacturing process of the active substance                                                                                                                                                                                                                                                                                            | 21/09/2007   | n/a   |                 |
| N/0103    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                   | 22/08/2007   | n/a   | PL              |
| IB/0102   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing | 22/08/2007   | n/a   | Annex II and PL |
| N/0098    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                   | 07/06/2007   | n/a   | PL              |

<div style=\"page-break-after: always\"></div>

| IB/0100   | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms IA_08_b_02_Change in BR/QC testing - repl./add. - incl. BC/testing   | 07/06/2007   | n/a        | PL                     | manuf. responsible for BR   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------|
| IB/0099   | IB_33_Minor change in the manufacture of the finished product                                                                                                                                                                                                     | 21/05/2007   | n/a        |                        |                             |
| IA/0101   | IA_32_b_Change in batch size of the finished product - downscaling down to 10-fold                                                                                                                                                                                | 15/05/2007   | n/a        |                        |                             |
| IA/0097   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                                                                                  | 23/03/2007   | n/a        |                        |                             |
| IA/0096   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                                                           | 21/03/2007   | 21/03/2007 | SmPC, Labelling and PL |                             |
| IA/0095   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                                                           | 21/03/2007   | 21/03/2007 | SmPC, Labelling and PL |                             |
| IA/0094   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                                                           | 21/03/2007   | 21/03/2007 | SmPC, Labelling and PL |                             |
| IA/0093   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                                                           | 21/03/2007   | 21/03/2007 | SmPC, Labelling and PL |                             |
| IA/0092   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                                                           | 21/03/2007   | 21/03/2007 | SmPC, Labelling and    |                             |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                         |            |            | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0091 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                                                                                                                                                 | 21/03/2007 | 21/03/2007 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0090 | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                                       | 15/01/2007 | n/a        | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0074 | This variation refers to changes in section 5.1 of the SPC to include the results of a trial studying the use of CoAprovel as 1st line treatment in patients with severe hypertension. The product information has also been updated according to the latest QRD templates. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 16/11/2006 | 11/01/2007 | SmPC, Annex II, Labelling and PL | Efficacy and safety of Karvezide as initial therapy for severe hypertension (defined as SeDBP 110 mmHg) was evaluated in a multicentre, randomised, double-blind, active- controlled, 8-week, parallel-arm study. A total of 697 patients were randomised in a 2:1 ratio to either irbesartan/hydrochlorothiazide 150 mg/12.5 mg or to irbesartan 150 mg and systematically force-titrated (before assessing the response to the lower dose) after one week to irbesartan/hydrochlorothiazide 300 mg/25 mg or irbesartan 300 mg, respectively. The study recruited 58% males. The mean age of patients was 52.5 years, 13% were 65 years of age, and just 2% were 75 years of age. Twelve percent (12%) of patients were diabetic, 34% were hyperlipidemic and the most frequent cardiovascular condition was stable angina pectoris in 3.5% of the participants. The primary objective of this study was to compare the proportion of patients whose SeDBP was controlled (SeDBP < 90 mmHg) at Week 5 of treatment. Forty-seven percent (47.2%) of patients on the combination achieved trough SeDBP < 90 mmHg compared to 33.2% of patients on |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                    |            |     |    | approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at 5 weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively (p < 0.0001). The types and incidences of adverse events reported for patients treated with the combination were similar to the adverse event profile for patients on monotherapy. During the 8 week treatment period, there were no reported cases of syncope in either treatment group. There were 0.6% and 0% of patients with hypotension and 2.8% and 3.1% of patients with dizziness as adverse reactions reported in the combination and monotherapy groups, respectively.   |
|---------|----------------------------------------------------------------------------------------------------|------------|-----|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0089 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                   | 09/01/2007 | n/a |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0088 | IA_15_a_Submission of Ph. Eur. certificate for active substance - approved manufacturer            | 12/12/2006 | n/a |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0087 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) | 05/12/2006 | n/a |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0085 | IB_10_Minor change in the manufacturing process of the active substance                            | 29/11/2006 | n/a |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| N/0086  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 16/11/2006 | n/a | PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0084 | IB_33_Minor change in the manufacture of the finished product                                      | 10/11/2006 | n/a |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|         | IA_32_a_Change in batch size of the finished product - up to 10-fold                               |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|----------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0083 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                   | 11/09/2006 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0082 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) | 30/08/2006 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| X/0071  | Annex I_2.(c) Change or addition of a new strength/potency                                         | 28/06/2006 | 28/08/2006 | SmPC, Labelling and PL | The new presentation consist in one new tablet strength 300/25 mg of film-coated tablets (irbesartan and hydrochlorothiazide). Pack sizes are: 14, 28, 56, 84 and 98 blister packs and 56 unit-dose blister pack. The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. The bioequivalence study performed by the MAH is considered the most sensitive design to detect differences in the performance of the formulations. The trial was able to adequately characterise the exposure to irbesartan and hydrochlorothiazide, and demonstrated that all three formulations, 300 mg/25 mg coated and uncoated Irbesartan/ hydrochlorothiazide Tablets and 2 150 mg/12.5 mg Avalide Tablets, are bioequivalent. |
| IB/0081 | IB_10_Minor change in the manufacturing process of the active substance                            | 21/08/2006 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0080 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                   | 17/07/2006 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| IA/0079   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                 | 17/07/2006   | n/a        |                 |
|-----------|--------------------------------------------------------------------------------------------------|--------------|------------|-----------------|
| IA/0078   | IA_09_Deletion of manufacturing site                                                             | 11/07/2006   | n/a        | Annex II and PL |
| IB/0075   | IB_10_Minor change in the manufacturing process of the active substance                          | 28/06/2006   | n/a        |                 |
| IA/0077   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                 | 22/06/2006   | n/a        |                 |
| IA/0076   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                 | 20/06/2006   | n/a        |                 |
| IB/0073   | IB_10_Minor change in the manufacturing process of the active substance                          | 29/03/2006   | n/a        |                 |
| II/0069   | Quality changes                                                                                  | 26/01/2006   | 06/02/2006 |                 |
| N/0072    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 19/01/2006   | n/a        | PL              |
| IB/0070   | IB_10_Minor change in the manufacturing process of the active substance                          | 16/01/2006   | n/a        |                 |
| N/0066    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 13/01/2006   | n/a        |                 |
| IB/0068   | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)         | 29/11/2005   | n/a        |                 |

<div style=\"page-break-after: always\"></div>

| IB/0067   | IB_10_Minor change in the manufacturing process of the active substance                            | 15/11/2005   | n/a        |                        |
|-----------|----------------------------------------------------------------------------------------------------|--------------|------------|------------------------|
| IA/0065   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) | 28/09/2005   | n/a        |                        |
| IA/0064   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) | 28/09/2005   | n/a        |                        |
| IA/0063   | IA_01_Change in the name and/or address of the marketing authorisation holder                      | 20/09/2005   | n/a        | SmPC, Labelling and PL |
| IB/0060   | IB_14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site  | 16/09/2005   | n/a        |                        |
| IA/0062   | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                   | 15/09/2005   | n/a        |                        |
| IA/0061   | IA_05_Change in the name and/or address of a manufacturer of the finished product                  | 12/09/2005   | n/a        | Annex II and PL        |
| IB/0058   | IB_10_Minor change in the manufacturing process of the active substance                            | 01/09/2005   | n/a        |                        |
| IA/0059   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size            | 18/08/2005   | 18/08/2005 | SmPC, Labelling and PL |
| IA/0057   | IA_11_b_Change in batch size of active substance or intermediate - downscaling                     | 03/08/2005   | n/a        |                        |

<div style=\"page-break-after: always\"></div>

|         | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                 | 10/02/2005   | n/a        | SmPC, Annex II, Labelling and PL   | IA/0056   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------------------|-----------|
| IB/0055 | IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing | 13/01/2005   | n/a        | Annex II and PL                    |           |
| II/0044 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                  | 16/09/2004   | 28/10/2004 | SmPC and PL                        |           |
| IA/0054 | IA_11_a_Change in batch size of active substance or intermediate - up to 10-fold                                                                                                                  | 17/09/2004   | n/a        |                                    |           |
| IB/0053 | IB_10_Minor change in the manufacturing process of the active substance                                                                                                                           | 10/08/2004   | n/a        |                                    |           |
| II/0046 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                  | 03/06/2004   | 02/08/2004 | SmPC and PL                        |           |
| IB/0052 | IB_14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site                                                                                                 | 29/07/2004   | n/a        |                                    |           |
| IB/0051 | IB_14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site                                                                                                 | 28/07/2004   | n/a        |                                    |           |
| IB/0048 | IB_10_Minor change in the manufacturing process of the active substance                                                                                                                           | 01/07/2004   | n/a        |                                    |           |
| IA/0050 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                          | 30/06/2004   | n/a        | Annex II and PL                    |           |

<div style=\"page-break-after: always\"></div>

|         | in BR/QC testing - repl./add. responsible for BR - not incl. BC/testing                                                                                                         |            |            |                                  | IA_08_b_01_Change manuf.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------|
| IA/0049 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                | 30/06/2004 | n/a        | Annex II and PL                  |                            |
| IB/0047 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site IB_07_c_Replacement/add. of manufacturing site: All other manufacturing operations ex. batch release | 20/04/2004 | n/a        |                                  |                            |
| IB/0045 | IB_14_a_Change in manuf. of active substance without Ph. Eur. certificate - change in manuf. site                                                                               | 14/04/2004 | n/a        |                                  |                            |
| X/0040  | X-3-iv_Change or addition of a new pharmaceutical form                                                                                                                          | 22/10/2003 | 02/03/2004 | SmPC, Annex II, Labelling and PL |                            |
| R/0041  | Renewal of the marketing authorisation.                                                                                                                                         | 25/09/2003 | 04/12/2003 | SmPC, Annex II, Labelling and PL |                            |
| I/0042  | 11b_Change in supplier of an intermediate compound used in manufacture of the active substance                                                                                  | 31/10/2003 | 12/11/2003 |                                  |                            |
| I/0043  | IB_10_Minor change in the manufacturing process of the active substance                                                                                                         | 10/11/2003 | n/a        |                                  |                            |
| II/0037 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                | 26/06/2003 | 02/10/2003 | SmPC and PL                      |                            |

<div style=\"page-break-after: always\"></div>

| I/0039   | change of manufacturing process of the substance                                                 | 12/06/2003   | 26/06/2003   |    | 12_Minor active   |
|----------|--------------------------------------------------------------------------------------------------|--------------|--------------|----|-------------------|
| I/0038   | 12_Minor change of manufacturing process of the active substance                                 | 11/06/2003   | 26/06/2003   |    |                   |
| I/0036   | 11_Change in or addition of manufacturer(s) of active substance                                  | 23/04/2003   | 25/04/2003   |    |                   |
| N/0034   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 04/04/2003   | 16/05/2003   | PL |                   |
| I/0035   | 20a_Extension of shelf-life or retest period of the active substance                             | 21/03/2003   | 01/04/2003   |    |                   |
| N/0033   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 17/01/2003   | 07/03/2003   | PL |                   |
| I/0032   | 12_Minor change of manufacturing process of the active substance                                 | 19/12/2002   | 17/01/2003   |    |                   |
| N/0031   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 03/12/2002   | 15/01/2003   | PL |                   |
| I/0029   | 15_Minor changes in manufacture of the medicinal product                                         | 05/06/2002   | 18/06/2002   |    |                   |
| N/0030   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 07/06/2002   | 28/06/2002   | PL |                   |
| I/0026   | 24a_Change in test procedure for starting material/intermediate used in manuf. of active         | 10/04/2002   | 02/05/2002   |    |                   |

<div style=\"page-break-after: always\"></div>

|         | substance                                                                                          |            |            |                        |
|---------|----------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| I/0028  | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance | 10/04/2002 | 30/04/2002 |                        |
| I/0027  | 20_Extension of shelf-life as foreseen at time of authorisation                                    | 20/02/2002 | 18/04/2002 | SmPC                   |
| II/0018 | Update of Summary of Product Characteristics and Package Leaflet                                   | 20/09/2001 | 10/04/2002 | SmPC and PL            |
| I/0025  | 01_Change following modification(s) of the manufacturing authorisation(s)                          | 22/12/2001 | 08/03/2002 | Annex II and PL        |
| I/0024  | 04_Replacement of an excipient with a comparable excipient                                         | 12/10/2001 | 26/02/2002 |                        |
| I/0022  | 30_Change in pack size for a medicinal product                                                     | 20/09/2001 | 19/02/2002 | SmPC, Labelling and PL |
| I/0021  | 30_Change in pack size for a medicinal product                                                     | 20/09/2001 | 19/02/2002 | SmPC, Labelling and PL |
| I/0020  | 30_Change in pack size for a medicinal product                                                     | 13/07/2001 | 08/10/2001 | SmPC, Labelling and PL |
| I/0019  | 30_Change in pack size for a medicinal product                                                     | 13/07/2001 | 08/10/2001 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|         | 03_Change in the name and/or address of the marketing authorisation holder                         | 20/09/2001   | n/a        | SmPC, Labelling and PL   | I/0023          |
|---------|----------------------------------------------------------------------------------------------------|--------------|------------|--------------------------|-----------------|
| I/0017  | 12_Minor change of manufacturing process of the active substance                                   | 26/04/2001   | n/a        |                          |                 |
| II/0014 | Update of Summary of Product Characteristics and Package Leaflet                                   | 14/12/2000   | 23/04/2001 | SmPC and PL              |                 |
| I/0016  | 01_Change following modification(s) of the manufacturing authorisation(s)                          | 04/04/2001   | n/a        | Annex II and PL          |                 |
| I/0015  | 26_Changes to comply with supplements to pharmacopoeias                                            | 20/03/2001   | n/a        |                          |                 |
| I/0013  | 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance | 21/11/2000   | n/a        |                          |                 |
| II/0012 | Update of Summary of Product Characteristics and                                                   | 27/07/2000   | 16/11/2000 | SmPC and PL              | Package Leaflet |
| I/0009  | 12_Minor change of manufacturing process of the active substance                                   | 21/12/1999   | 20/05/2000 |                          |                 |
| N/0010  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 18/01/2000   | 24/03/2000 | PL                       |                 |
| N/0009  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 11/11/1999   | 03/02/2000 | PL                       |                 |

<div style=\"page-break-after: always\"></div>

| I/0008   | 15_Minor changes in manufacture of the medicinal product                                             | 08/09/1999   | 22/09/1999   |    |
|----------|------------------------------------------------------------------------------------------------------|--------------|--------------|----|
| I/0007   | 11b_Change in supplier of an intermediate compound used in manufacture of the active substance       | 08/09/1999   | 22/09/1999   |    |
| I/0006   | 12a_Change in specification of starting material/intermediate used in manuf. of the active substance | 01/06/1999   | 07/06/1999   |    |
| N/0005   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)     | 26/03/1999   | 07/05/1999   | PL |
| I/0004   | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process       | 19/02/1999   | n/a          |    |
| I/0003   | 16_Change in the batch size of finished product                                                      | 19/02/1999   | n/a          |    |
| I/0002   | 11_Change in or addition of manufacturer(s) of active substance                                      | 05/02/1999   | n/a          |    |
| I/0001   | 11b_Change in supplier of an intermediate compound used in manufacture of the active substance       | 20/01/1999   | n/a          |    |